1.	Phase I/II Study of Paclitaxel and Radiotherapy With or Without Trastuzumab (Herceptin®) in Patients Who Have Undergone Prior Transurethral Bladder Resection for Muscle-Invasive Transitional Cell Carcinoma of the Bladder Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0524, NCT00238420
2.	Phase II of Study Neoadjuvant Cisplatin, Bevacizumab, and Gemcitabine Hydrochloride Followed By Radical Cystectomy and Adjuvant Bevacizumab and Paclitaxel in Patients With Muscle-Invasive, Nonmetastatic, Resectable Transitional Cell Carcinoma of the Bladder Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: MUSC-AVF-3312, 100892, MUSC-HR-15537, GENENTECH-AVF-3312, NCT00268450, MUSC-CTO-100892
3.	Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
4.	Phase II Study of Neoadjuvant and Adjuvant Erlotinib Hydrochloride in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UNC-LCCC-0521, LCCC 0521, NCT00380029
5.	Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0620, NCT00506155
6.	Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2007.061, NCT00585689
7.	Phase II Randomized Study of Neoadjuvant Polyphenon® E (Defined Green Tea Catechin Extract) in Patients With Nonmetastatic Bladder Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WCCC-UWI06-8-01, UWI06-8-01, CO06810, H2007-0250, 07-1270-03, NCT00666562
8.	Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 2007-0704, NCT00749892
9.	Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MCC-15441, IRB 10718, NCT00751140
10.	Phase II Randomized Study of Chemoradiotherapy Comprising Fluorouracil, Cisplatin, and Radiotherapy Versus Gemcitabine Hydrochloride and Radiotherapy Followed By Selective Bladder Preservation and Adjuvant Chemotherapy Comprising Gemcitabine Hydrochloride and Cisplatin in Patients With Stage II or III Muscle-Invasive Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Tumor Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0712, RTOG 0712, NCT00777491
11.	Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-208, NCT00808639
12.	Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-159, NCT00847015
13.	Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HOG GU07-123, NCT00859339
14.	Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder Phase: Phase II Type: Natural history/Epidemiology, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007-0441, NCT00963859
15.	Phase I Study of Neoadjuvant Intravesical Recombinant Fowlpox-TRICOM Vaccine and/or Recombinant Fowlpox-Sargramostim Vaccine in Patients With Bladder Carcinoma Undergoing Cystectomy Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: CINJ-3909, NCI-5585, NCT00072137, 5585
16.	Phase I Randomized Study of Short-Term Low-Dose Interferon alfa in Patients With Cancer of the Urothelium Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: MDA-ID-030172, NCT00082719
17.	Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06C.549, NCT00437372
18.	A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2008_541, NCT00753415
19.	Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
20.	Respiratory Tumor and Normal Tissue Motion Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2003-0962, NCT00415675
21.	Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU07-122, NCT00706641
22.	Pilot Study of Catheter-Based Ultrasound Hyperthermia Therapy After Brachytherapy in Patients With Urologic, Gynecologic, or Head and Neck Cancer Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCSF-08992, 08992, H10778-32056, NCT00911079
23.	Study of 3 Tesla MRI and Ex-Vivo Ultra-High-Field MRI Imaging in Patients With Bladder Cancer Phase: No phase specified Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-08063, OSU-08063, 2009C0001, NCT00938145
24.	Comparison of Standard of Care or Treatment on Protocol Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST 0813, NCT01010334